Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic neuropathic pain, today announced compelling topline data from its Phase 2a clinical ...

Patients with and without obesity experienced significant pain reductions and improved functioning following telerehabilitation for chronic musculoskeletal pain.

The following is a summary of “Real-world satisfaction and experience with injection and autoinjector device for ofatumumab ...

Vertex Pharmaceuticals ( VRTX 5.31%) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Cebranopadol reduced pain intensity in patients following abdominoplasty surgery in the ALLEVIATE-1 clinical trial.

On Amazon, a good product rating percentage is generally considered to be 80% or higher, which corresponds to a four-star ...

The following is a summary of “Pain Assessment and Management in Oncological Practice: A Survey from the Italian Network of ...

On day 28 of the trial, patients taking Spravato exhibited numerical improvements for all 10 items on the Montgomery-Asberg ...

Allosteric GABAA-receptor modulator AP-325 showed rapid onset as well as long-lasting pain reduction in patients with chronic neuropathic pain in Phase 2a study Data confirm previously reported ...